Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
9.25
-0.18 (-1.91%)
At close: Jul 26, 2024, 4:00 PM
9.29
+0.04 (0.43%)
After-hours: Jul 26, 2024, 7:28 PM EDT
Iovance Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 134.19 | 114.89 | 231.73 | 78.23 | 67.33 | 13.97 | Upgrade
|
| Short-Term Investments | 222.01 | 164.98 | 240.11 | 426.18 | 562.11 | 293.11 | Upgrade
|
| Cash & Short-Term Investments | 356.2 | 279.87 | 471.85 | 504.41 | 629.44 | 307.08 | Upgrade
|
| Cash Growth | -43.13% | -40.69% | -6.46% | -19.86% | 104.97% | -34.46% | Upgrade
|
| Receivables | 0.23 | 0.15 | - | - | - | - | Upgrade
|
| Inventory | 17.62 | 10.37 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 11.49 | 17.46 | 7.27 | 3.55 | 6.66 | 9.41 | Upgrade
|
| Total Current Assets | 385.53 | 307.85 | 479.12 | 507.96 | 636.1 | 316.49 | Upgrade
|
| Property, Plant & Equipment | 183.31 | 176.55 | 178.25 | 169.92 | 113.92 | 19.23 | Upgrade
|
| Long-Term Investments | - | - | - | 91.59 | - | - | Upgrade
|
| Other Intangible Assets | 294.3 | 229.26 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | 6.69 | 66.7 | 6.62 | 7.87 | 18.44 | 8.93 | Upgrade
|
| Total Assets | 869.83 | 780.35 | 663.98 | 777.33 | 768.46 | 344.66 | Upgrade
|
| Accounts Payable | 25.7 | 33.12 | 26.6 | 27.38 | 13.51 | 15.57 | Upgrade
|
| Accrued Expenses | 44.78 | 66.97 | 45.79 | 51.91 | 30.73 | 16.27 | Upgrade
|
| Current Portion of Leases | 11.08 | 7.78 | 12.59 | 5.06 | 6.28 | 7.25 | Upgrade
|
| Other Current Liabilities | 1.66 | 2.44 | 6.51 | 4.86 | 4.34 | - | Upgrade
|
| Total Current Liabilities | 83.21 | 110.31 | 91.49 | 89.2 | 54.87 | 39.08 | Upgrade
|
| Long-Term Debt | 1 | 1 | 1 | 1 | - | - | Upgrade
|
| Long-Term Leases | 72.29 | 67.09 | 71.86 | 65.47 | 45.38 | 4.25 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 33.3 | 17.35 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 11.71 | 2.35 | Upgrade
|
| Total Liabilities | 189.81 | 195.74 | 164.34 | 155.67 | 111.96 | 45.68 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 2,805 | 2,594 | 2,069 | 1,795 | 1,487 | 869.35 | Upgrade
|
| Retained Earnings | -2,125.35 | -2,012.38 | -1,568.34 | -1,172.45 | -830.19 | -570.61 | Upgrade
|
| Comprensive Income & Other | 0.12 | 2.53 | -0.9 | -0.6 | 0.02 | 0.22 | Upgrade
|
| Total Common Equity | 680.02 | 584.61 | 499.64 | 621.66 | 656.49 | 298.97 | Upgrade
|
| Shareholders' Equity | 680.02 | 584.61 | 499.64 | 621.66 | 656.5 | 298.97 | Upgrade
|
| Total Liabilities & Equity | 869.83 | 780.35 | 663.98 | 777.33 | 768.46 | 344.66 | Upgrade
|
| Total Debt | 84.37 | 75.86 | 85.45 | 71.53 | 51.66 | 11.5 | Upgrade
|
| Net Cash (Debt) | 271.83 | 204.01 | 386.4 | 432.88 | 577.78 | 295.58 | Upgrade
|
| Net Cash Growth | -49.95% | -47.20% | -10.74% | -25.08% | 95.47% | -36.91% | Upgrade
|
| Net Cash Per Share | 1.09 | 0.87 | 2.43 | 2.82 | 4.18 | 2.38 | Upgrade
|
| Filing Date Shares Outstanding | 279.83 | 279.31 | 224.24 | 157.17 | 146.98 | 126.5 | Upgrade
|
| Total Common Shares Outstanding | 279.76 | 256.14 | 187.81 | 157 | 146.87 | 126.41 | Upgrade
|
| Working Capital | 302.32 | 197.54 | 387.63 | 418.76 | 581.23 | 277.41 | Upgrade
|
| Book Value Per Share | 2.43 | 2.28 | 2.66 | 3.96 | 4.47 | 2.37 | Upgrade
|
| Tangible Book Value | 385.72 | 355.35 | 499.64 | 621.66 | 656.49 | 298.97 | Upgrade
|
| Tangible Book Value Per Share | 1.38 | 1.39 | 2.66 | 3.96 | 4.47 | 2.37 | Upgrade
|
| Machinery | 33.39 | 33.27 | 31.79 | 14.87 | 5.41 | 5.25 | Upgrade
|
| Construction In Progress | 23.96 | 24.1 | 9.12 | 35.78 | 56.76 | 5.42 | Upgrade
|
| Leasehold Improvements | 76.85 | 76.8 | 74.31 | 57.82 | 2.57 | 2.37 | Upgrade
|
Source: S&P Capital IQ. Standard template.